Trial Profile
A Phase 1, Open-Label Study in Hemodialysis and Non-Hemodialysis Patients With Severe Chronic Kidney Disease to Evaluate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Ocedurenone (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors KBP Biosciences
- 21 May 2020 According to a KBP Biosciences media release, safety and pharmacokinetic results from the study were published online in MedRxiv (https://doi.org/10.1101/2020.05.12.20053314).
- 21 May 2020 Results presented in a KBP Biosciences media release.
- 08 Mar 2018 Status changed from active, no longer recruiting to completed.